Your source for all Prime Therapeutics' November 2024 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for November 2024 will keep you informed on what’s trending now.

Released November 27, 2024

Clinical Highlights: November 2024

An overview od clinical insights' trending topics and timely drug information highlights. This month covers Nordisk’s semaglutide (Ozempic), shortages of stimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) and more.

November Drug Approvals

A review of our newly approved specialty drugs, recent drug launches and new indications in the last month, including zolbetuximab-clzb (Vyloy), obecabtagene autoleucel (Aucatzyl) and more.

Released November 21, 2024

NEW PUBLICATION: GLP-1 Pipeline Update

This newly launched quarterly publication provides a view of the GLP-1 pipeline and anticipated indications. See what's coming in the GLP-1 pipeline.

Released November 20, 2024

High-Cost Therapy Profile

Providing a clinical deep dive into a select high cost drug in the pipeline. This month’s profile features proposed indications for pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC).

Released November 15, 2024

FDA Decisions Expected for December 2024

A breakdown of FDA decisions expected of new drugs expected to hit the market. This edition covers concizumab, denosumab (CT-P41), revakinagene taroretcel (NT-501) and more.

All brand names are property of their respective owners.